Reaction Details Report a problem with these data
Target
Malignant T-cell-amplified sequence 1
Ligand
BDBM403230
Substrate
n/a
Meas. Tech.
MTT assay
EC50
80.0±n/a nM
Citation
 Bannister, TD; Roush, WR; Choi, JY; Nair, R; Tsai, AS; Mishra, JK; Cleveland, JL Heterocyclic inhibitors of monocarboxylate transporter US Patent  US10329303 Publication Date 6/25/2019 
Target
Name:
Malignant T-cell-amplified sequence 1
Synonyms:
MCT-1 | MCT1 | MCTS1 | MCTS1_HUMAN | Multiple copies T-cell malignancies
Type:
Enzyme Catalytic Domain
Mol. Mass.:
20563.62
Organism:
Homo sapiens (human)
Description:
n/a
Residue:
181
Sequence:
MFKKFDEKENVSNCIQLKTSVIKGIKNQLIEQFPGIEPWLNQIMPKKDPVKIVRCHEHIEILTVNGELLFFRQREGPFYPTLRLLHKYPFILPHQQVDKGAIKFVLSGANIMCPGLTSPGAKLYPAAVDTIVAIMAEGKQHALCVGVMKMSAEDIEKVNKGIGIENIHYLNDGLWHMKTYK
  
Inhibitor
Name:
BDBM403230
Synonyms:
US10329303, Example 29
Type:
Small organic molecule
Emp. Form.:
C29H28FN3O2
Mol. Mass.:
469.5499
SMILES:
CC(C)Cc1nn(C)c(=O)c2c(-c3cccc(CO)c3F)n(Cc3cccc4ccccc34)cc12 |(-5.32,-5.95,;-5.32,-4.41,;-6.65,-3.64,;-3.98,-3.64,;-3.98,-2.1,;-5.32,-1.33,;-5.32,.21,;-6.65,.98,;-3.98,.98,;-3.98,2.52,;-2.65,.21,;-1.18,.69,;-.79,2.18,;-1.88,3.26,;-1.48,4.75,;.01,5.15,;1.1,4.06,;2.59,4.46,;2.99,5.95,;.7,2.57,;1.79,1.49,;-.28,-.56,;1.26,-.56,;2.03,-1.89,;1.26,-3.23,;2.03,-4.56,;3.57,-4.56,;4.34,-3.23,;5.88,-3.23,;6.65,-1.89,;5.88,-.56,;4.34,-.56,;3.57,-1.89,;-1.18,-1.8,;-2.65,-1.33,)|
Structure:
Search PDB for entries with ligand similarity: